

## Adakveo® (crizanlizumab-tmca)

When requesting Adakveo® (crizanlizumab-tmca), the individual requiring treatment must be diagnosed with an FDA-approved indication and meet the specific coverage guidelines and applicable safety criteria for the covered indication.

### FDA-approved Indication

Adakveo is indicated to reduce the frequency of vasoocclusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease.

### Coverage Guidelines

#### Sickle cell disease (SCD)

The individual must meet all of the following criteria for authorization:

- Is 16 years of age or older; AND
- Adakveo is prescribed by or in consultation with a physician who specializes in the treatment of sickle cell disease (e.g., a hematologist).

**Approval duration: 12 months**

### Dosing Recommendation

Approve up to 5 mg/kg administered by intravenous infusion at week 0, week 2, and then not more frequently than once every 4 weeks.

### References

1. Adakveo® injection for intravenous use [prescribing information]. East Hanover, NJ: Novartis; November 2019.
2. Piel FB, Steinberg MH. Sickle cell disease. *N Engl J Med*. 2017;376:1561-1573.
3. The National Institutes of Health – National Heart, Lung, and Blood Institute Evidence-Based Management of Sickle Cell Disease, Expert Panel Report 2014. Available at: <http://www.nhlbi.nih.gov/guidelines>. Accessed on November 18, 2019.